
Opinion|Videos|April 11, 2025
Advancing Retinal Disease Treatment – The Next Generation of Anti-VEGF Therapies
Listen
0:00 / 0:00
Ehsan Rahimy, MD; David G. Miller, MD, and Jordana Fein, MD, discusses how 8 milligram aflibercept and faricimab, newer anti-VEGF therapies for retinal diseases, offer improved durability with comparable safety profiles to existing treatments, allowing less frequent injections while maintaining equivalent vision outcomes.
Advertisement
Timecodes:
1:25- Rationale for high dose aflibercept
5:00- PULSAR trial for AMD
12:00- PHOTON trial for DME
16:21- Changing practice patterns
22:29- Faricimab and role of ang-2 inhibition
28:30 Impact of new therapies
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Q&A: Intensive LDL Lowering and Cardiovascular Prevention Strategies, With Lawrence Leiter, MD
2
Evaluating Clinical and Real-World Evidence in Hypercortisolism
3
Management Strategies for Hypercortisolism
4
Interstitial Lung Abnormalities: Recognition, Risk Stratification, and When to Act
5






















































































